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Genomic medicine and the use of genetic information in pediatric oncology has provided 
insight on the molecular underpinnings of childhood cancers and has demonstrated that cancer 
predisposition syndromes (CPS) are underdiagnosed. Diagnosis of a CPS has important 
implications for the patient and their family. In childhood, CPS are often diagnosed by geneticists 
or oncologists with expertise in CPS following a malignancy, however, this requires a member of 
the care team, most commonly, the treating oncologist to suspect a CPS and refer them for 
assessment. We sought to understand current referral practices of pediatric oncology healthcare 
providers and barriers to referral for evaluation of a CPS. An online survey was sent to members 
of the Children’s Oncology Group. Of the 189 respondents, 80.4% were pediatric 
hematologists/oncologists and most (69%) used formal guidelines to aid in referral assessment. 
Guideline use was associated with a higher proportion (>5%) of patients with a CPS in the 
respondent’s practice. Participants were more likely to refer patients with malignancy and 
additional features of a CPS than for a specific type of cancer, despite the use of guidelines. Most 
respondents indicated they would rarely refer patients with tumors highly associated with CPS. 
Patient/parent knowledge of family history was considered the most challenging barrier to 
obtaining a family history, though a thorough three-generation pedigree was not consistently 
attempted.  Overall, participants indicated the most significant barrier to referral was priority given 
the patient’s more immediate care needs. Other barriers to genetics referral identified elsewhere 
v 
by primary care physicians were unlikely to be considered barriers in this population. These data 
suggest that pediatric hematologists/oncologists experience different barriers than other specialties 
and may benefit from further education about CPS, and clearer referral guidelines. Furthermore, 
utilization of a genetic counselor within the pediatric oncology clinic may encourage CPS 
assessment but allow oncologists to focus on the patient’s immediate care needs. These findings 
may facilitate increased referrals for CPS evaluation which improve public health by identifying 
patients and families who may benefit from preventative care measures.   
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Pathogenic germline mutations in cancer predisposition genes confer an increased lifetime 
risk for cancer and are classified as cancer predisposition syndromes (CPS). Historical 
observational data predicted 10% of all pediatric cancers were due to a CPS, however, in the era 
of genomic sequencing, data now suggest 7.6-35.5% of childhood cancers are due to an underlying 
CPS.1-10 While prevalence varies due to a number of factors, these data suggest that overall, CPS 
are underdiagnosed in the pediatric population.  
Early diagnosis of individuals with a CPS improves patient outcomes by informing 
management and surveillance, and may have familial implications.10-13 Referral guidelines have 
been established to aid practitioners in the identification of patients who would benefit from further 
assessment by a genetics professional.14-17 It is currently unknown how often children with a 
suspected CPS are referred for further evaluation but rates of genetic referral uptake for adult 
oncology range from 22-68%.18-22 If rates are similar for the pediatric population, there may be a 
significant number of CPS cases undiagnosed due to low referral uptake, however, if referral does 
not occur, uptake is irrelevant. Numerous barriers to genetics referrals have been identified in other 
specialties but data in the pediatric oncology setting are sparse.19,23-32  
The specific aims of this study were to: 
i. Understand referral practices of pediatric oncology healthcare providers (HCP) for 
patients with a suspected CPS 
ii. Define recommendations to improve genetics referrals for patients with a 
suspected CPS by pediatric oncology HCP 
2 
The Children’s Oncology Group (COG) is a pediatric cancer research group supported by 
the National Cancer Institute. It was chosen as the study population because its members make up 
a large proportion of pediatric oncology HCP in America. Survey design was modelled after 
published studies in other medical disciplines, with additional questions formulated to address 
issues specific to pediatric oncology.  The goals of this project were to elucidate current referral 
practices of pediatric oncology HCP, to identify perceived barriers to referral for patients with a 
suspected CPS, and to formulate recommendations to improve referral behaviors of pediatric 
oncology HCP for patients with a suspected CPS. 
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2.0 Literature Review 
2.1 Pediatric Cancer 
Cancer is the most common cause of death by disease in children aged 1-14 in the United 
States. In 2019, an estimated 11,060 children will be diagnosed with cancer and nearly 11% will 
die from their disease. Survival rates vary by tumor type and age at diagnosis; the overall survival 
for a child diagnosed with neurofibromatosis type 1 and optic glioma is 100% compared to 40% 
for a child with low hypodiploid acute lymphoblastic leukemia, a leukemia commonly associated 
with Li Fraumeni syndrome (LFS).33-35 
Identification of individuals with a cancer predisposition syndrome may reduce pediatric 
cancer mortality by utilizing prevention and early detection measures. Current research aims to 
identify novel treatments that will decrease the mortality rate in the pediatric cancer population, as 
standard agents are often ineffective in advanced disease. More specifically, 30-40% of standard 
of care chemotherapeutics are ineffective in metastatic, refractory, or relapsed pediatric solid 
tumors.6 In addition to more effective therapeutics, screening and/or risk reducing surgery may be 
beneficial when a predisposing germline mutation has been identified in a child. In fact, 
preventative measures have been found to improve outcomes for individuals with cancer 
predisposition syndromes such as LFS  and multiple endocrine neoplasia type II.13,36  
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2.2 Cancer Predisposition Syndromes 
Cancer predisposition syndromes (CPS) are caused by pathogenic germline mutations in 
tumor suppressor genes, or more rarely oncogenes, which confer an increased risk for cancer. A 
number of professional societies recognize the importance of early detection of cancer in 
individuals with a CPS.14,15,17,37 Early detection may benefit the patient and his or her family in a 
number of ways including disease management options, screening and prevention for the patient 
and family members, and providing an answer for why a child has cancer.11  
LFS provides an example of the benefit of identifying individuals with a CPS and 
implementing cancer surveillance. LFS is caused by germline loss of function mutations in TP53, 
resulting in multiple primary tumors and/or tumors at a young age (often before age 30).38-40 
Characteristic LFS cancers include tumors of the breast, brain, adrenal cortex, and bone and soft 
tissue sarcomas. Early identification of LFS allows for comprehensive screening beginning at 
birth, avoidance of radiation therapy which is associated with increased secondary tumor risk, and 
testing/screening of family members.41 Clinical surveillance of individuals with LFS increases 5-
year overall survival from 59.6% to 88.8%.13  
To begin surveillance at birth, there must already be a suspicion or diagnosis of a CPS in 
the family, which stresses the importance of obtaining a thorough and complete family history in 
the oncology and primary care setting. An Australian study of 648 childhood cancer survivors, 
illustrated the importance of revisiting family history information. Of the survivors, 2% (16/648) 
reported they had been diagnosed with a CPS since their cancer diagnosis, however, following 
analysis of their family history, 11% (69/648) met Chompret criteria for clinical diagnosis of LFS. 
The median time between cancer diagnosis and family history update for the study was 16 years 
(range: 5-43 years).42 Unfortunately, for those individuals with a de novo mutation or a CPS with 
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lower penetrance, they may be the first in the family to be identified following a cancer diagnosis.  
Other indications a child should be assessed for a CPS include specific physical features, high risk 
tumor types, and incidental findings from germline or somatic testing.15  
While some CPS are associated with additional characteristics, there are several reasons 
why individuals with physical features of a CPS may not be diagnosed.17 The time surrounding a 
pediatric cancer diagnosis is usually stressful and clinical efforts are often focused on treatment 
options. Furthermore, due to variable expressivity, not all individuals with a CPS have suggestive 
physical features, and there is also evidence that pediatricians and oncologists whose training does 
not focus on genetic syndromes, may not recognize the physical signs of such rare disorders.1,11,43  
Merks and colleagues argue all children diagnosed with cancer should be evaluated by a 
clinical geneticist or other provider skilled in dysmorphology. Following physical examination of 
1,073 children with cancer, they diagnosed 3.9% (42/1073) with a CPS and identified 3.3% 
(35/1073) with a suspected CPS.43 Their research suggests genetics specialists with 
dysmorphology expertise are the appropriate HCP to diagnose these individuals. A study of 370 
childhood cancer survivors found 29% (109/370) were eligible for genetics follow up based on 
personal/family medical history and published literature as assessed by a genetic counselor, 
indicating a proportion of individuals with a CPS may be missed by standard referral routes and 
genetics specialists should be involved in CPS assessment.44  
2.2.1 Prevalence of Cancer Predisposition Syndromes 
Previously, cancer registries and family studies predicted about 10% of all pediatric cancers 
were due to an underlying CPS.1,10 Further research has focused on identifying genetic drivers of 
tumorigenesis with the use of next generation sequencing (NGS).2,3,5-9 These studies aim to 
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identify novel drug targets, guide tumor surveillance protocols, identify patients that may benefit 
from genetic counseling and/or a genetics assessment, and provide empirical prevalence data. 
Collectively, sequencing data suggest between 7.6-35.5% of pediatric cancers are due to 
pathogenic germline mutations. When comparing studies, germline mutation frequency varies by 
tumor type, study population, and the authors’ definition of a “reportable pathogenic germline 
mutation”. The two largest pediatric cancer sequencing studies report 7.6% (N=914) and 8.5% 
(N=1,120) of patients possess a pathogenic or likely pathogenic germline mutation in a cancer 
predisposition gene.2,3 The studies differ in the number of cancer predisposition genes analyzed 
(162 genes vs. 60 genes, respectively), nonetheless, they are concordant with the historical 
prediction of 10%. These cohorts included a broad range of pediatric tumors from multiple centers 
in the United States and Europe. Importantly, there was overlap in the samples between these two 
studies. 
Two additional pediatric pan-cancer studies sequenced patients with relapsed, refractory, 
or rare diseases, poor prognosis and/or a suspected CPS. Mody and colleagues identified 9.9% 
(9/91) of patients with a cancer-related pathogenic germline finding. Of these, 4/9 patients had no 
remarkable family history of cancer.4 Comparatively, Oberg et al. found 20% (18/90) of patients 
in their study had a pathogenic germline mutation. Overall, 14% of their cohort had a mutation in 
a cancer predisposition gene.5 This study included analysis of the American College of Medical 
Genetics and Genomics (ACMG) secondary finding genes, a list of 59 medically actionable genes 
recommended by the ACMG to be returned to patients undergoing clinical sequencing, 
demonstrating the utility of these recommendations.45,46 
As NGS continues to be utilized in the clinic, recommendations such as those described 
for return of secondary findings above, will be prudent when genetic test interpretation is not 
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straight forward.45,46 In a group of relapsed/refractory tumors representative of 20 distinct non-
central nervous system (CNS) solid tumors, 11.8% (7/59) of patients had a pathogenic germline 
mutation in a known cancer predisposition gene, similar to previously discussed studies. 
Interestingly, one patient had a mutation in one allele each of TSC1 and TSC2 which would not be 
reportable alone, however, the researchers felt that together these data represented reportable 
findings.6 This demonstrates the complexity of interpreting germline mutations, in that genetic 
modifiers should be carefully considered. 
Two small studies of patients at high risk for a CPS found a larger proportion of patients 
with pathogenic germline mutations than expected. The first analyzed patients with a CNS tumor 
and the following criteria: uncertain histological diagnosis, unsuccessful standard of care 
treatment, and/or disease that progressed through prior therapies. Of these patients, 35.5% (11/31) 
had germline pathogenic mutations indicative of a CPS including Li-Fraumeni syndrome and 
Gorlin syndrome, some of whom had no family history.7 Similarly, a study of 40 children with 
cancer and at least one of the following features: intellectual disability and/or congenital 
anomalies, multiple primary cancers, positive family history, or adult cancer type, identified 20% 
(8/40) of patients carried a pathogenic germline mutation, 3 of which were pathogenic DICER1 
mutations.8 The samples in these studies were from small, high risk populations, and thus are likely 
an over-representation of CPS in pediatric cancer patients. However, they highlight the importance 
of considering a CPS in this group of patients and the utility of whole exome sequencing.  
In comparison, Parsons et al. sequenced a cohort of patients with treatment naïve solid 
tumors to determine the diagnostic yield of clinical tumor and germline whole exome sequencing 
in this population. Ten percent (15/150) of patients were found to have a pathogenic or likely 
pathogenic germline mutation, a similar estimate to other pan-cancer data.9  
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Lastly, certain subtypes of sarcoma are associated with CPS, such as osteosarcoma in LFS, 
and malignant peripheral nerve sheath tumors in neurofibromatosis type 1.40,47 However, recent 
sequencing data suggest a higher prevalence of CPS than expected in some subtypes. For example, 
whole exome sequencing of 1,004 patients with osteosarcoma found 28% (281/1004) had a 
pathogenic germline mutation in a cancer predisposition gene, seven of which had not previously 
been associated with this type of cancer.48 Similarly, a recent case report described the first 
germline mutation in the DNA damage repair gene, BARD1, in a Ewing sarcoma patient.49 Ewing 
sarcomas are not within the spectrum of any known CPS, however,  Brohl et al. sequenced 175 
tumors and found 13.1% (23/175) of patients had pathogenic germline mutations in a cancer 
predisposition gene.50 As our knowledge of the genetic landscape of pediatric cancers continues 
to evolve, our definition of CPS-associated phenotypes and medically actionable genes may 
require revision.  
The aforementioned sequencing studies suggest that generally, around 10% of pediatric 
cancers and as many as 35.5% of high-risk patients with CNS cancers are due to an underlying 
CPS. As NGS becomes a standard clinical tool, the phenotypic spectrum of well-characterized 
CPS will broaden and novel genotypic-phenotypic associations will continue to be identified. 
Together, the prevalence of pathogenic germline mutations in cancer predisposition genes and the 
identification of cancer survivors who are eligible for genetics follow up, suggest evaluation for a 
CPS may be warranted in more children with cancer than previously thought.44  
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2.3 Barriers to Genetics Referrals  
CPS are underdiagnosed in children, as indicated by research carried out by genetics 
specialists.43,44 This suggests then, that in order to diagnose more children with a CPS, appropriate 
referrals to genetics providers with expertise in CPS must increase.  
There are multiple ways in which a patient may access genetics services. The National 
Society of Genetic Counselors (NSGC) Service Delivery Model Task Force classified specific 
modes of referral as: traditional, tandem, triage, rescue, or self-referral.51 With the exception of 
self-referral, all entry points to genetics work-up require a non-genetics healthcare provider to 
recognize a genetic condition and to subsequently refer the patient to a genetics specialist such as 
a genetic counselor or geneticist. Barriers to genetics referral have been well described in the 
literature with a focus on primary care and adult oncology practices and can be broadly classified 
as knowledge, evidence, and system barriers.  
2.3.1 Barrier: Provider Knowledge 
One of the most complex barriers to genetics referral is provider knowledge. This includes 
the provider’s own genetics knowledge, confidence in explaining and managing patients based on 
genetics results, and knowledge of available genetic tests.  
2.3.1.1 Genetics Knowledge 
Qualitative and quantitative studies from around the world indicate physicians who do not 
specialize in genetics feel they lack sufficient knowledge of genetics as well as the confidence to 
discuss  such topics with their patients.24-26,29,52,53 A recent meta-analysis of perceived barriers to 
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genetics services found that 22 out of the total 38 studies identified lack of physicians’ genetics 
knowledge as a barrier to services.23 For instance, a survey of 82 physicians including PCPs, 
gynecologists, surgeons, and oncologists, found 67% felt more cancer genetics education would 
improve patient identification for cancer genetics referral.32 In a prenatal setting, the self-assessed 
clinical genetics knowledge of PCPs was a mean of 5, or moderate, on a scale of 0-10 (N=99).54 
Further, Trinidad et al. found American PCPs not only lacked genetics knowledge, but were also 
concerned about the time it would take and the ease at which to access the most current 
information.26  
Data collected from 1,427 physicians in Ontario, Canada found that while 91% were aware 
of genetic testing available for hereditary breast and ovarian cancer, only 60% were aware of 
similar testing for hereditary colon cancer. Those with high confidence in genetics competencies, 
like family history taking and cancer risk assessment, were more likely to refer their patients for 
genetic counseling. When compared to oncologists, PCPs were less likely to refer patients for 
genetic evaluation, and similarly, of the physicians in the aforementioned Brandt et al. study, PCPs 
were significantly less comfortable identifying patients for genetics referral and discussing 
genetics with their patients than specialists.25,32 This discomfort has been described in qualitative 
interviews including a study of general practitioners (GPs) (the equivalent to American PCPs), in 
the UK that found some asked their patients to return at a later date once they had time to review 
important genetic information.29 Interviews of oncologists who had referred patients to The 
Michigan Oncology Sequencing Project at the University of Michigan, a paired tumor/normal 
genome sequencing research project with the goal of providing personalized oncology care, 
indicated assistance from a genetic counselor would be valuable for both the physician and the 
patient in clarifying results and their implications for care.55 These data are supported by a 
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quantitative study of 363 Canadian physicians which found only 21% of family physicians, 
cardiologists and oncologists felt sufficiently informed about genetic testing in the context of 
precision medicine.56  
As this research suggests, identification of genetic syndromes requires specialized 
knowledge. Whole exome sequencing of paired germline and pediatric tumors has provided 
examples of previously undiagnosed patients with a CPS who were diagnosed following 
sequencing. Parsons et al. identified 3/8 patients not previously offered genetic testing but who 
possessed germline mutations in dominant cancer susceptibility genes associated with a childhood 
risk for cancer. One patient had a pathogenic MSH2 mutation and a family history suggestive of 
Lynch syndrome. A thorough family history was not elicited during the patient’s treatment for 
glioblastoma. The second patient had a plexiform neurofibroma, multiple anomalies, and a likely 
pathogenic germline KRAS mutation and had not been clinically diagnosed with Noonan 
syndrome. Lastly, a patient with unilateral Wilms tumor was mosaic for a WT1 mutation and did 
not have typical congenital anomalies or developmental delay.9 These cases demonstrate both the 
clinical utility of NGS in oncology and the level of detailed knowledge required for diagnosis of 
some CPS including the importance of personal and family medical history information, and 
knowledge of complex genetics principles. 
Knowledge about CPS has not been assessed in PCPs, pediatricians, or pediatric oncology 
HCP. Although the data above regarding physicians’ knowledge about genetics are specific to 
adult oncology or primary care, they highlight a key issue with current referrals: genetics 
knowledge is essential to increase appropriate referrals for genetic evaluation but is currently 
lacking for non-genetics providers.  The specific HCP required to be knowledgeable about CPS 
depends on patient presentation. Patients with a family history of a CPS may be identified by a 
12 
PCP or pediatrician when they are asymptomatic, whereas pediatric hematologists/oncologists 
may identify symptomatic children. This suggests that various pediatric HCP should be considered 
when addressing knowledge about CPS and referral of these patients to genetics. 
2.3.1.2 Family History Information 
One aspect of genetics knowledge that is studied more specifically is the elicitation and 
quality of family history information. Multiple studies indicate that while PCPs gather family 
history information and appreciate its utility, it is unlikely to be complete.24,27,57,58 The majority 
(94.7%) of American Academy of Pediatrics (AAP) members surveyed between 2013-2014 (N = 
349) indicated they believe family history information is important in determining disease risk and 
managing a patient’s care.28 Yet an additional survey of American pediatricians and family doctors 
(N = 448) indicated only 11% of respondents collected a full 3-generation history and only 2.8% 
reported constructing a pedigree. These researchers also found that participants gathered family 
history information using a linear rather than degree of relationship-focused approach. For 
example, while 66.7% of participants collected information on grandparents, 30.7% collected 
information on aunts and uncles even though both are second degree relations to the child. The 
researchers suggest the lack of information gathered on aunts and uncles may be insufficient to 
identify genetic conditions.27 
For oncology patients, poor family history elicitation can result in missed or delayed 
referrals to genetics. A prospective study of 387 adult colorectal cancer patients compared self-
reported patient histories with physician notes following an initial gastroenterology oncology 
clinic evaluation. The authors found 41% (127/311) of physician notes did not record a 
comprehensive family history of cancer. In fact, the more family members with cancer, the less 
likely the physician was to take a more detailed family history.57 These data indicate the 
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importance of accurate and thorough family history taking and illustrate familial gastrointestinal 
cancer risk was not appropriately assessed by oncologists.  
A more recent study of oncology practices belonging to the American Society of Clinical 
Oncology’s Quality Oncology Practice Initiative, demonstrated that family history information 
was incomplete (missing information on first- and second-degree relatives, and age at cancer 
diagnosis for those with cancer) for more than 60% of patients with breast or colorectal cancer. In 
addition, providers were less likely to elicit a complete family history or refer for genetic 
counseling/testing for patients with colorectal cancer compared to breast cancer. This trend 
continued even after accounting for differences between populations.22  
In addition to the technique by which physicians gather family history information, barriers 
to a complete history identified by HCP include inadequate time during routine visits to collect or 
update information, inaccurate or incomplete information from patients, and increased disease 
complexity.24,28,53,57,59-61 In a pediatric oncology setting, there are additional challenges to family 
history elicitation due to the emotional effects of a pediatric cancer diagnosis, discussion of 
treatment plans and scheduling imaging appointments, and it is often deferred.1 
The importance of family history information is emphasized by the association between 
personal and/or family history of cancer and higher likelihood of referral to a genetics 
specialist.19,62 A retrospective study in the United Kingdom (UK) aimed to describe the reasoning 
of GPs for referring an asymptomatic patient with a family history of cancer to a genetics clinic. 
Of the patients, 89% (63/71) reported they had initiated the discussion about their family history 
of cancer which led to the genetics referral. This was confirmed by the physicians. The most 
common reason patients initiated discussion was a recent cancer event in the family, yet only 20% 
(14/71) of patients recalled being asked details about their family history. Consistent with other 
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research, the GPs felt a lack of knowledge in genetics, confidence in taking a detailed family 
history, and lack of patient knowledge hindered their ability to take a thorough family history. 
Furthermore, 69% (N = 36) of the physicians in this study indicated a diagnostic clinic was the 
preferred referral route for asymptomatic patients unless the patient specifically asked for a referral 
to genetics. Ninety two percent of GPs did not know, or knew very little about the genetics clinic 
they referred to.24 This study again illustrates that PCPs lack appropriate genetics knowledge to 
ensure relevant information is collected, but also that genetics referrals for asymptomatic 
individuals with a family history of cancer are largely patient-driven. 
While similar studies of pediatricians or pediatric oncologists could not be identified, a 
recent survey assessed parental attitudes to genetic counseling and/or testing. The group surveyed 
parents of children recently diagnosed with cancer and found that 64.3% (27/42) were familiar 
with genetic counseling and that 50% (21/42) were interested in pursuing genetic 
counseling/testing but referral was not offered to 59.5% (25/42).63 Interest in genetic testing was 
not dependent on personal or family history of cancer or features suggestive of a CPS as described 
by Jongmans et al.11 Thus, the authors suggest that it is reasonable to consider referral to genetics 
for evaluation of a CPS despite family history in a pediatric oncology setting.63 
Together, these data suggest genetics specialists are being underutilized whether due to the 
urgency of cancer treatment planning and disease management, or lack of genetics knowledge in 
the referring physician. While there is evidence to suggest that oncologists and other specialists 
feel more comfortable identifying patients at high risk for a CPS than PCPs, genetics specialists 
continue to identify these individuals in populations previously screened by other HCP, indicating 
poor family history taking and/or over emphasis of a negative family history are barriers to genetics 
referrals.43,44,56,57  
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2.3.2 Barrier: Evidence 
Another barrier that is closely related to provider knowledge is evidence. This includes 
providers’ understanding of the clinical utility of genetics information, as well as the use of tools 
designed to simplify and streamline genetics concepts.  
2.3.2.1 Perceived Clinical Utility 
There is qualitative evidence that suggests a physician’s professional identity plays a role 
in resistance to including genetics as part of their practice in the UK. Twenty-one GPs were 
interviewed regarding their views on clinical genetics. Major themes that emerged included the 
distinction between family history taking and clinical genetics. One physician indicated genetics 
concepts did not “fit with GPs’ thought processes”.29 This theme indicates that while knowledge 
of genetics concepts may be lacking in GPs, more research and work needs to be done to stress the 
relevance of genetics as a whole to a GP or PCP’s practice.   
Interestingly, studies have shown that a number of physicians perceive a lack of therapeutic 
intervention for genetic conditions and thus feel it is inappropriate to collect such information from 
patients especially since it may cause anxiety.26,29 Further, some physicians do not refer patients 
for genetics evaluation because they believe it will not change patient management, or suspect 
genetic tests do not return meaningful results.30,64 While these data were collected over ten years 
ago, current studies suggest some physicians maintain these beliefs despite the growth and 
utilization of genomic medicine. A study of 157 practicing physicians from Texas found 56% 
(88/157) reported genetics was slightly or not at all integral to patient care in their specialty. More 
specifically, 24% (8/34) of family or internal medicine physicians indicated genetics was 
moderately or very integral compared to 92% (24/26) of obstetricians/gynecologists. Further, 72% 
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(113/157) of survey respondents rarely or never referred patients to genetic counseling which 
correlated with perceived importance. These data suggest the perceived value of genetics affects 
likelihood of genetics referral.65 
Not surprisingly, most research in this field indicates PCPs and GPs find it difficult to keep 
up with genetics as a discipline, which contributes to their lack of confidence in providing patient 
risk assessment, addressing ethical and legal concerns, and interpreting genetic test results.26,31,53 
Genetics educational programs aimed at PCPs have been proven to increase knowledge and 
confidence of genetics topics.66 Nonetheless, a study of 24 PCPs in the US indicated a preference 
for “just-in-time” resources and educational programs that address “red flags” rather than 
comprehensive genetics training programs.26 These data suggest that there is a lack of urgency to 
implement genetics into primary care practice, perhaps due to a misunderstanding of its 
importance.  
2.3.2.2 Tools 
Accessibility and utility of tools such as referral guidelines, and awareness of genetics 
services have the potential to improve appropriate genetics referrals. Many qualitative studies have 
indicated physicians felt clear, concise guidelines were lacking.24,28,29,57,67 
Professional societies (American Cancer Society, ACMG/NSGC, American Association 
for Cancer Research, German Society for Pediatric Oncology and Hematology) and academic 
collaborations (McGill Interactive Pediatric OncoGenetic Guidelines) have established and 
continue to update practice guidelines for cancer predisposition assessment in order to standardize 
risk assessment criteria.14-17,68 All aim to provide concise, easy to understand guidelines to identify 
pediatric and/or adult oncology patients at risk for a CPS who should be referred for genetic 
consultation. 
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Despite these efforts, evidence indicates that referral rates for adult patients who meet 
published guidelines for referral to a cancer genetics clinic vary widely between 22-68%. Referrals 
are more likely for patients cared for in academic versus community centers, patients with breast 
cancer rather than gynecologic or colorectal cancer, closer geographical distance to the care center, 
and non-African American race.18-22 
Some research suggests that lack of adherence to guidelines is closely related to genetics 
knowledge and perceived clinical utility of genetic counseling or genetic testing. One survey of 
gastroenterologists found that while 79% of physicians appropriately identified a pedigree 
suspicious for Lynch syndrome, only 16% recommended the correct screening based on published 
guidelines and only 34% of respondents were aware that genetic testing for Lynch syndrome was 
available. Those who did not recommend genetic testing for the proband were more likely to agree 
that genetic testing is not beneficial. In addition, 48% of respondents were unaware that genetic 
testing for familial adenomatous polyposis (FAP) was available.69 FAP is a CPS that includes risks 
for childhood cancer such as hepatoblastoma and colon cancer. Individuals with FAP may begin 
cancer surveillance in infancy or childhood if a mutation is identified, illustrating the importance 
of genetic testing in these individuals.70 Another study of adults with colorectal cancer found that 
19% (75/387) of patients met Bethesda guidelines for assessment for Lynch syndrome, a CPS with 
adult onset cancers, however only 17% (13/75) of eligible individuals were referred for genetic 
evaluation.57 While there have been advancements in genetics education since these studies were 
completed, they nonetheless indicate a lack of understanding of CPS, lack of adherence to 
established guidelines, and fewer referrals to genetics professionals which may affect cancer 
surveillance and mortality for at-risk individuals.71  
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Some clinics have addressed these issues by embedding genetic counseling services within 
adult oncology clinics or providing toolkits to aid in identifying appropriate referrals, both of 
which have been successful.62,72-74 In the adult oncology setting, interventions such as the 
introduction of a genetics referral toolkit demonstrate that education does increase genetics 
referrals. Beginning in 2014, the National Comprehensive Cancer Network and the Society of 
Gynecologic Oncology began to recommend genetic counseling and consideration of genetic 
testing for women with epithelial ovarian cancer (EOC) at any age.75,76 In a historical cohort of 81 
women with EOC seen at Mayo Clinic Rochester between July 1, 2013 and December 31, 2013, 
less than half (39/81) were referred for genetics consultation. The consensus guidelines as well as 
the implementation of a referral toolkit that consisted of a referral template, genetic risk checklist, 
and family history worksheet as well as education sessions for medical oncology, gynecologic 
surgery, and genetics professionals increased the referral rate of new patients by 26.1%.62  
Some gynecological cancer clinics have integrated genetic counselors into their practice 
increasing the visibility and availability of genetics services for women with ovarian cancer. 
American and Australian groups have reported an increased uptake of services and guideline 
compliance.72,73 More specifically, the American study found a 46% increase (38% pre-
intervention to 84% post-intervention) in genetic counseling appointments following the 
placement of a genetic counselor in the clinic which was consistent even on days when the genetic 
counselor was not physically present.72 Similarly, the Australian group found referrals increased 
from 54% pre-intervention to 85% post-intervention.73  
While the model for these interventions is simplified in that guidelines state all women 
with ovarian cancer be referred for genetic evaluation, genetics education and multidisciplinary 
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care teams that include genetic counselors increase referrals. These principles may be applied in 
the pediatric oncology setting as well. 
2.3.3 Barrier: System 
Physicians with the knowledge and tools to suspect a patient has a CPS may still encounter 
system barriers to referral. A survey of American PCPs in the early 2000s indicated 67% (n=190) 
felt accessibility to face-to-face genetics consultation was difficult or unavailable. Similarly, 58% 
felt accessibility to remote genetics consultation was difficult or unavailable. Respondents were 
asked to estimate the proportion of visits in which they discussed a genetic condition and the 
subsequent proportion that resulted in referral to genetics. For each condition discussed, less than 
half were referred. Patients with congenital anomalies were referred by almost half of physicians 
(48%) which theoretically may have included some CPS relevant in childhood. Patients with a 
family history of breast and/or ovarian cancer were referred by 14% of physicians, whereas those 
with a family history of colon cancer were referred by 7%.31 While the quantification of these 
referrals is likely subject to recall bias due to study design, this work suggests accessibility to 
genetics services is a major factor in referral practices for PCPs. Other barriers identified by 
respondents were patient concerns, or ethical/social issues which included unclear guidelines.31    
2.3.3.1 Accessibility 
Many aspects of the referral process may reduce accessibility. In the adult oncology setting, 
a national survey of PCPs, internal medicine, and obstetrics and gynecology specialists found that 
45.9% (365/795) of physicians did not refer patients for genetics evaluation when a CPS was 
suspected. While inconvenient location of referral was a reason not to refer for 22.7% (83/365) of 
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physicians, 24.6% (90/365) were unaware of the method by which to refer patients. Stratification 
of responses by referral preference indicated that physicians located further than 10 miles from a 
genetic counselor were less likely to refer (68.7%), suggesting that location as well as knowledge 
of the referral process creates a barrier to genetics referral. The two most common reasons for not 
referring patients with a suspected CPS to genetics were uncertainty of which patients to refer 
(38.3%) and concerns about cost (37.2%). Only 9% (33/365) of physicians indicated they would 
initiate testing themselves, and another 9.3% (34/365) felt genetics information was not useful in 
patient management, suggesting a significant number of patients in whom a CPS was suspected 
would not appropriately be followed or managed.30  
Some studies have documented that shorter geographic distance to a genetic counselor or 
academic center is more likely to result in referral for genetic assessment in an adult oncology 
setting. Retrospective analysis of 696 women diagnosed with epithelial ovarian cancer at the 
University of Virginia between 2004 and 2015 found that living more than 100 miles away from 
a genetics center was less likely to result in referral (OR 0.49; 95% CI 0.28-0.86) compared to 50 
miles away or less. A distance of 50-100 miles from a genetics center was not significantly 
different from less than 50 miles (OR 0.72; 95% CI 0.46-1.15). The authors point out that although 
guidelines changed to recommend genetics referral for all women diagnosed with EOC during the 
study period, a third of women were still not being referred 2 years following the introduction of 
these guidelines.19 Therefore, despite professional guidelines, a large proportion of women were 
not being referred appropriately, and proximity to a facility that provides genetics services is a 
possible contributing factor.  
In the pediatric setting, professional guidelines recommend genetics evaluation for children 
with developmental delay. In Alabama, 43% (59/137) of pediatricians surveyed referred to 
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genetics as the first step in their evaluation. Distance to a genetics center was a reason not to refer 
for only 12% (16/137), indicating a difference in approach compared to adult oncology. In fact, 
physicians who practiced further than 100 miles away from a genetics center were more likely to 
refer patients (53%) compared to those between 50-100 miles (24%) and less than 50 miles 
(38%).64 While this and the study by Acheson et al. did not directly compare indications and the 
likelihood of referral for genetics evaluation, these data suggest pediatric patients are more likely 
to be referred to genetics for visible concerns rather than theoretical risks such as a family history 
of cancer.31 
Accessibility to genetics professionals impacts the likelihood that patients with genetic 
conditions will be referred. In an adult oncology setting, close proximity to a genetics center is 
more likely to result in referral, however, knowledge and evidence factors including the improper 
use of professional guidelines also contribute to inaccessibility. In contrast, in pediatrics, there is 
evidence to suggest that the further the distance, the more likely the child will be referred. It is 
unclear how these factors contribute when assessing children for a CPS.  
2.3.3.2 Cost 
Multiple studies have cited that lack of insurance coverage or cost for genetic services is a 
barrier to genetics referrals.30-32,64,67 As described above, the second most common reason 
physicians indicated they would not refer a patient for genetic counseling was cost (136/365, 
37.2%).30 Similarly, of 82 PCPs and specialist physicians surveyed regarding their referral 
practices to a cancer genetics program, approximately 33% were unaware that testing laboratories 
accept insurance and that approval is not uncommon.32 Another survey of 1,251 physicians 
including PCPs, tertiary care physicians, and oncologists indicated 59.8% agreed with the 
statement that genetic tests for CPS are not usually covered by patients’ health plans.67 While this 
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study addresses genetic testing rather than genetic counseling or referral to a genetics specialist, 
the results suggest cost is a relevant concern for many providers.  
Cost is also a concern for patients. A retrospective study of women who had received 
genetic counseling and cancer risk assessment from a cancer center in Arizona between 2002 and 
2004, found that insurance coverage and lower cost of genetic testing were significant predictors 
of test uptake.77 Women with breast or ovarian cancer identified through the Utah Cancer Registry 
also indicated test costs and insurance coverage were reasons for delayed uptake or declined testing 
(38.9%, n=142).78 While these studies focused on women who obtained genetic counseling, they 
indicate that cost and insurance coverage factor into patient as well as physician decision-making 
in the context of genetics services. 
2.4 Summary 
Early diagnosis of a CPS and subsequent cancer surveillance improves patient outcomes. 
Furthermore, diagnosis of an individual may lead to diagnosis of other family members. In this 
way, identifying patients with an underlying CPS and utilizing preventative care measures 
improves public health. Knowledge, evidence, and systems barriers to genetics referral for 
evaluation of a CPS are prevalent and described in the literature as it pertains to adult oncology or 
general pediatrics. There is a lack of research focused on the referral practices of pediatric 
oncologists to genetics programs for evaluation of childhood onset CPS. The goal of this study is 
to address this gap in knowledge by surveying American healthcare providers involved in the care 




Cancer predisposition syndromes (CPS) are caused by pathogenic germline mutations in 
tumor suppressor genes, or more rarely oncogenes, which confer an increased lifetime risk for 
cancer. Historical data predicted 10% of all pediatric cancers were due to a CPS.1,10 Empirical data 
now suggest 7.6-35.5% of childhood cancers are due to an underlying CPS.2-9 Even so, 
retrospective studies of childhood cancer survivors have identified children that are eligible for 
genetic evaluation or meet clinical disease criteria.42,44 Furthermore, extrapolation of CPS 
prevalence data to childhood cancer survivors predicts 11.8% carry a pathogenic germline 
mutation in a cancer predisposition gene.79 While the proportion of individuals with a CPS varies 
based on tumor type, study population, and classification of mutations, these data illustrate that 
overall, CPS are underdiagnosed in the pediatric population.  
Individuals with a CPS are at an increased risk to develop treatment toxicity and secondary 
tumors, and thus benefit from early diagnosis, which may inform management and surveillance.10-
13 Diagnosis of a CPS may occur in symptomatic individuals following a personal history of 
cancer, or asymptomatic individuals following identification of a CPS in the family. To facilitate 
the identification of patients with a suspected CPS, referral guidelines have been established.14-17 
Rates of genetic referral uptake for pediatric oncology patients are unknown but can be inferred 
from studies in adult oncology. Genetic referral uptake rates range from 22-68% in this setting, 
and vary based on physician and patient factors.18-22 
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Numerous barriers to genetics referrals have been identified in the primary care and adult 
oncology literature and can be broadly categorized as knowledge, evidence, and system barriers. 
Research suggests that providers feel they do not possess the specialized knowledge or confidence 
required to discuss genetic conditions with their patients, and some physicians believe additional 
cancer genetics education would improve patient identification for cancer genetics referral.24-
26,32,52,53 
Despite professional guidelines to aid in identification of patients appropriate for referral, 
some healthcare providers (HCP) perceive genetic services lack clinical utility and are not integral 
to their practice.30,64,65 Unsurprisingly, this perception has been linked to lack of genetics 
knowledge and adherence to guidelines.65,69 Although PCPs have indicated it is difficult to keep 
up with genetics as a discipline, which contributes to their lack of confidence, they prefer 
abbreviated resources rather than comprehensive genetics training programs.26,31,53  
System barriers to genetics referral include access to genetics services and/or professionals. 
In adult oncology, further distance from a genetic counselor or genetics clinic has been correlated 
with decreased referral likelihood for CPS evaluation.19,30 In addition, some research suggests that 
the referral process itself may be a hinderance, as many PCPs are unaware of which clinic to refer 
to or how to initiate the process.24,25,30 Cost has also been considered a barrier to genetics referral 
by the HCP and uptake by the patient.30-32,80 
Given that most research on the topic of barriers to genetics referrals focuses on data from 
primary care and adult oncology, this study investigates current referral practices of HCP involved 
in the care of pediatric oncology patients with a suspected CPS. We surveyed members of the 
Children’s Oncology Group (COG) to understand how they currently assess patients for genetics 




An electronic survey link was emailed to 3,219 physicians who were active members of 
COG and who indicated their specialty was hematology/oncology, surgery, pathology, cellular 
therapy, or cytogenetics. In total, 230 responses were returned. Forty-one responses were excluded 
because they were incomplete. The total number of complete responses was 189. The response 
rate was 5.8%.  
Eligible participants were healthcare providers involved in pediatric oncology care located 
in the United States. All responses were anonymized. Participants were encouraged to forward the 
survey link to their eligible colleagues. Responses were recorded February 5, 2020 – March 2, 
2020. A reminder was sent one week prior to closure of the survey. This study was approved by 
the University of Pittsburgh Institutional Review Board as an exempt protocol (STUDY19090002) 
(Appendix B).  
3.2.2 Survey Design 
The survey consisted of six sections: demographics, family history, barriers, knowledge, 
accessibility, and genetic testing. The demographics section included questions about the 
participant and details about their practice. The family history section asked respondents how they 
collect family history information. The barriers section included questions about perceived barriers 
to family history collection and referrals. Questions about specific cancer types and features of 
CPS were part of the knowledge section. The accessibility section included questions about access 
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to genetics providers, use of referral guidelines, and access to other genetics services. The genetic 
testing section asked respondents about current genetic testing practices and comfort with genetic 
test results. Questions were modeled after published surveys distributed to other medical 
specialties or designed by the authors to address gaps in knowledge. Some questions allowed 
respondents to select multiple answers. The survey was piloted before distribution by E.K., 
K.M.B., R.G., and J.M. to ensure questions were relevant, straight forward, free of errors, and to 
ensure flow. It was administered using the Qualtrics survey platform accessed through a University 
of Pittsburgh license. The survey can be found in Appendix D. 
3.2.3 Statistical Analysis 
Data were analyzed by descriptive statistics. Totals vary by question as some questions 
allowed respondents to select all choices that apply. Proportion of response was calculated based 
on the number of total responses for each individual question. Pearson’s χ2 test was used to assess 
relationships between guideline use and demographic factors. Z-test for proportions was used to 
compare guideline use and Likert scale questions. Analyses were performed with Stata (v.16).  
3.3 Results 
3.3.1 Demographics 
Participant demographic data are summarized in Table 1. The majority of respondents were 
staff physicians (80.4%, 152/189), other respondents were MD/DO fellows (15.3%, 29/189), PhDs 
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(7.4%,14/189), or a genetic counselor (0.5%, 1/189). Of those participants who possessed a PhD, 
13/14 were also MDs.  
The majority of respondents identified their specialty as hematology/oncology (70.4%, 
131/186). Additional specialties included surgery (7.5%, 14/186), pediatrics (3.8%, 7/186), 
pathology (1.6%, 3/186), genetics (0.5%, 1/186), or other (3.8%, 7/186). Those participants who 
chose other indicated specialties in ophthalmology, pediatric urology, subspecialties of oncology 
(orthopedic oncology, neuro-oncology), or multiple specialties such as genetics and oncology.  
Over half of respondents were between 30-49 years old (67.7%, 126/186). Almost a quarter 
(24.3%, 45/185) of respondents have been practicing for less than five years. Similarly, 23.2% 
(43/185) have practiced for over 20 years, with the remaining participants practicing between 5-
10 years (20%, 37/185), 11-20 years (19.5%, 36/185), or currently training (24/185, 13%). There 
was representation from each major region of America, though some states did not have a single 
respondent. 
The most common practice settings were children’s hospitals within an academic center 
(55.7%, 108/194), followed by freestanding children’s hospital (40.2%, 78/194). Others indicated 
their primary practice setting was part of a cancer center (2.1%, 4/194), private (1.5%, 3/194), or 
did not fit into the above categories (1.0%, 2/194). The size of each practice was estimated by 
clinical volume of new pediatric oncology patients per year. Most participants indicated a clinical 
volume of less than 100 patients (42.8%, 80/187) or 100-250 patients (36.9%, 69/187). 
Respondents were asked to estimate what proportion of patients seen in their clinic have a 
diagnosed CPS. These estimates were comparable to the known CPS population prevalence of 
approximately 10%. Those respondents who indicated more than 10% of their patients had a 
diagnosed CPS (6.5%, 12/186) practiced within a cancer predisposition clinic.  
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Table 1. Demographic characteristics of survey respondents. 
Characteristic Number (%) 
Level of training   
     MD (staff physician) 152 80.4 
     MD/DO (fellow) 29 15.3 
     PhD 14 7.4 
     Genetic counselor 1 0.5 
Specialty   
     Hematology/oncology 131 70.4 
     Surgery 14 7.5 
     Pediatrics 7 3.8 
     Pathology 3 1.6 
     Genetics 1 0.5 
     Other 7 3.8 
Age   
     ≤30 3 1.6 
     30-39 72 38.7 
     40-49 54 29.0 
     50-59 33 17.7 
     60-69 20 10.8 
     ≥70 4 2.2 
Years in practice   
     Currently training 24 13.0 
     Less than 5 45 24.3 
     5-10 37 20.0 
     11-20 36 19.5 
     20+ 43 23.2 
Practice location   
     Northeast (CT, ME, MA, NH, NJ, NY, PA, RI, VT) 37 20.1 
     Midwest (IA, IL, IN, KS, MI, MN, MO, NE, ND, OH, SD, WI) 45 24.5 
     South (AL, AR, DC, DE, FL, GA, KY, LA, MD, MS, NC, OK, SC, TN, TX, VA, WV) 71 38.6 
     West (AK, AZ, CA, CO, HI, ID, MT, NV, NM, OR, UT, WA, WY) 31 16.8 
Practice setting    
     Children's hospital within academic/university center 108 55.7 
     Freestanding children's hospital 78 40.2 
     Cancer Center 4 2.1 
     Private practice 3 1.5 
     Other 2 1.0 
Clinical volume (new pediatric oncology patients)   
     Less than 100 80 42.8 
     100-250 69 36.9 
     More than 250 35 18.7 
     Not currently seeing patients 3 1.6 
Proportion of patients with diagnosed CPS   
     None 2 1.1 
     Less than 5% 81 43.5 
     5-10% 65 34.9 
     More than 10% 12 6.5 
     Unsure 26 14.0 
CPS cancer predisposition syndrome   
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3.3.2 Access to Genetics Services  
Access to genetics professionals or a cancer predisposition clinic was elucidated to 
determine whether an association with referral attitudes existed. Greater than half (59.7%, 
108/181) of respondents indicated their institution had a cancer predisposition clinic, with 70.8% 
(75/108) situated within the pediatric hematology/oncology division (Table 2). Furthermore, 
97.3% (182/187) indicated they had access to a genetics specialist including a geneticist or genetic 
counselor. A large majority (87%, 160/184) of participants reported they consult with genetics or 
CPS specialists if they suspect a patient has a CPS. Feedback from the genetics clinic regarding 
referral appropriateness was common for 62.6% (114/182) of respondents. Some participants 
received feedback before referral at tumor board meetings or during consultations. Respondents 
were also asked to specify the sources through which they obtain information about genetics; 
scientific literature (95.2%, 177/186) and personal communication with genetics professionals 











Table 2. Access to genetics services. 
  Number (%) 
Institution has cancer predisposition clinic     
     Yes 108 59.7 
          Hematology/oncology 75 70.8 
          Medical genetics 25 23.6 
          Other 8 7.5 
     No  60 33.1 
     Unsure 13 7.2 
Access to a genetics specialist   
     Yes 182 97.3 
          Geneticist 152 83.5 
          Certified genetic counselor 162 89.0 
          Other   
               Oncologist with expertise in CPS 9 4.9 
               Molecular program 3 1.6 
     No 5 2.7 
Consult with a genetics specialist if suspect a CPS   
     Yes 160 87.0 
     No  4 2.2 
     Sometimes 18 9.8 
     N/A 2 1.1 
Receive feedback from a genetics clinic regarding referrals     
     Yes 114 62.6 
     No 48 26.4 
     Unsure 20 11.0 
Participate in molecular/genetics tumor boards     
     Yes 86 46.5 
     No, but occur within institution 59 31.9 
     No, there are none within institution 40 21.6 
Sources used to obtain information about genetics     
     Scientific literature 177 95.2 
     Fellowship/training 116 62.4 
     CME activities 76 40.9 
     Personal communication with genetics professionals 153 82.3 
     Multi-disciplinary tumor board meeting 141 75.8 
CPS cancer predisposition syndrome   
 
3.3.3 Referral Practices 
To investigate current referral practices, participants were asked who the most appropriate 
provider is to refer a patient with a CPS for genetics evaluation. The majority of respondents 
believed a hematologist/oncologist was most appropriate (83.9%, 151/180), whereas 5.6% 
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(10/180) thought a medical geneticist was most appropriate (Table 3). Conversely, participants felt 
medical geneticists (62%, 111/179) were the most appropriate provider to diagnose a patient with 
a CPS, whereas 19.6% (35/179) thought hematologists/oncologists and 12.8% (23/179) thought 
genetic counselors were most appropriate to diagnose.  
Respondents indicated that they rarely (42.6%, 78/183) or sometimes (30.1%, 55/183) 
referred patients for a CPS evaluation. Fewer than a quarter of respondents often (18.6%, 34/183) 
or frequently (2.7%, 5/183) referred patients for a CPS evaluation. Frequency was not correlated 
with use of referral guidelines. 
Formal referral guidelines were used always (34.2%, 63/184) or sometimes (34.8%, 
64/184) and most respondents were somewhat (44.4%, 56/126) or extremely (15.9%, 20/126) 
satisfied with the guidelines they use, while 32.5% (41/126) were indifferent. A quarter of 
participants (45/180) did not use the same guidelines as their colleagues, and 58.9% (106/180) 
were unsure of which, if any, guidelines their colleagues used. Use of guidelines was dependent 
on clinical volume of CPS patients (Pearson’s χ2, p = 0.01). 
The main reason for not using guidelines was the lack of guideline availability (34.4%, 
45/131), with an additional 8.4% (11/131) who were unaware guidelines existed. About a quarter 
(32/131) of participants felt confident referring without guidelines, and 15.3% (20/131) indicated 
conflicting guidelines from different sources discouraged their use. Other responses included the 
use of formal institutional guidelines (5/131), respondent considered another provider more 
appropriate to assess the patient (5/131), referral of all pediatric oncology patients to genetics 
(4/131), inconsistent application of guidelines (3/134), or unclear guidelines, lack of time to use 
guidelines, or still training (2/134). 
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Table 3. Referral practices. 
 Number (%) 
Most appropriate provider to refer for CPS evaluation   
     Hematologist/Oncologist 151 83.9 
     Medical geneticist 10 5.6 
     Genetic counselor 8 4.4 
     Primary care physician 2 1.1 
     Other 9 5.0 
Most appropriate provider to diagnose CPS   
     Hematologist/Oncologist 35 19.6 
     Medical geneticist 111 62.0 
     Genetic counselor 23 12.8 
     Pathologist 1 0.6 
     Other 9 5.0 
Referral frequency for CPS   
     Frequently (several times per week) 5 2.7 
     Often (several times per month) 34 18.6 
     Sometimes (once per month) 55 30.1 
     Rarely (a few times per year) 78 42.6 
     Never 7 3.8 
     N/A 4 2.2 
Use guidelines   
     Yes 63 34.2 
     No 57 31.0 
     Sometimes 64 34.8 
Satisfaction with current guidelines   
     Extremely satisfied 20 15.9 
     Somewhat satisfied 56 44.4 
     Neither satisfied nor dissatisfied 41 32.5 
     Somewhat dissatisfied 8 6.3 
     Extremely dissatisfied 1 0.8 
Providers within practice use the same guidelines   
     Yes 29 16.1 
     No 45 25.0 
     Unsure 106 58.9 
Main reason not using guidelines   
     Lack of available guidelines 45 34.4 
     Conflicting guidelines from different sources 20 15.3 
     Feel confident in referring without them 32 24.4 
     Other 34 25.4 
          Unaware of guidelines 11 8.4 
          Use institutional guidelines 5 3.8 
          Other provider more appropriate 5 3.8 
          Refer all 4 3.1 
          Not always applicable 3 2.3 
          Require clarification 2 1.5 
          Time 2 1.5 
          Still learning 2 1.5 
N/A not applicable   
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To elucidate the type of patients that participants may consider referring for evaluation of 
a CPS, they were asked how often they refer a patient with a given cancer for assessment. The list 
included cancers with different levels of recommendation for referral based on published 
guidelines. Of the cancer types recommended to result in referral regardless of family history, or 
other features suggestive of a CPS, pheochromocytoma/paraganglioma (PPGL) and choroid 
plexus carcinoma (CPC) were the most likely to always result in referral, however, this was only 
indicated by 31.3% (51/163) and 29.4% (47/160) of respondents (Figure 1A). Current guidelines 
suggest all cases of PPGL or CPC should be referred for assessment. Participants who used 
guidelines were significantly more likely to always refer a patient with PPGL (one tailed z-test, 
p<0.05).  
The majority of respondents indicated they rarely refer patients with medulloblastoma, 
osteosarcoma, embryonal/alveolar rhabdomyosarcoma, glioma, neuroblastoma, Wilms tumor, 
acute myeloid leukemia, or Ewing sarcoma. Most respondents also specified they rarely referred 
patients with Hodgkin lymphoma, a cancer that is often sporadic, for genetics referral. Hodgkin 
lymphoma was included to ensure the internal validity of the question.   
We then assessed the likelihood that a patient would be referred for evaluation of a CPS if 
they presented with a malignancy and additional features. Features were previously described by 
Jongmans et al. to be suggestive of a pediatric CPS and warrant referral to genetics.11 While the 
majority of respondents were likely to refer patients with each concerning feature, the certainty 
with which they did so varied. Well understood indications were extremely likely to be referred, 
such as a patient with a malignancy and genetic test results indicating a germline mutation in a 
cancer predisposition gene (89.1%, 164/184) or multiple malignancies (85.9%, 158/184) (Figure 
1B). In contrast, a patient presenting with a malignancy and developmental delay/intellectual 
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disability was extremely likely to be referred by only 12.5% (23/184) of respondents, with most 
somewhat likely (45.1%, 83/184) or neither likely nor unlikely (34.2%, 63/184) to refer for genetic 
evaluation indicating physician uncertainty despite published guidelines that recommend referral 
for these indications.11,14,17 
When familiarity with published guidelines for referral/evaluation of a CPS was used to 
stratify responses, those who did not use guidelines were significantly less likely to refer patients 
with a malignancy and immune deficiency (one tailed z-test, p<0.05). Overall likelihood to refer 
patients with other features were not associated with guideline use, however tendency (extremely 
vs somewhat likely or unlikely) was significantly associated for some features. Patients with 
features of abnormal growth such as macrocephaly, or hemihyperplasia were extremely likely to 
be referred by 41.2% (52/126) of respondents who used referral guidelines compared to 23.6% 
(13/55) of respondents who did not use referral guidelines (one tailed z-test, p<0.05). Those 
participants who did not use guidelines still indicated they were somewhat likely to refer patients 
with abnormal growth (60%, 33/55). A similar trend was observed for the patients with excessive 
toxicity to cancer therapy; 23.8% (30/126) of respondents who use guidelines were extremely 
likely to refer compared to 10.9% (6/55) of those who do not use guidelines (z-test, p<0.05). These 
data suggest that guideline use increases confidence in appropriate referrals. 
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Figure 1. Likelihood to refer for CPS evaluation.  A. Likelihood of respondents to refer a patient for evaluation of 
a CPS based on disease type. B. Likelihood of respondents to refer a patient for evaluation of a CPS based on features 
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as decribed by Jongmans et al.11 Abbreviations: CPC choroid plexus carcinoma, MB medulloblastoma, PPGL 
pheochromocytoma/paraganglioma, OS osteosarcoma, ERMS embryonal rhabdomyosarcoma, ARMS alveolar 
rhabdomyosarcoma, GLI glioma, NB neuroblastoma, WT Wilms tumor, ES Ewing sarcoma, HL Hodgkins lymphoma, 
DD/ID developmental delay/intellectual disability. 
3.3.4 Family History Elicitation 
Family history was considered essential to assessment of new pediatric oncology patients 
by greater than 90% of respondents regardless of whether or not a CPS was suspected (Appendix 
A, Table 1). However, research suggests that adult oncologists do not collect complete family 
history information. To investigate whether this applies to pediatric health care providers, we asked 
respondents to indicate the frequency with which they ask about particular family members when 
eliciting family history for a routine pediatric oncology patient or a pediatric oncology patient with 
a suspected CPS (Table 4). Regardless of evaluation type, almost all respondents always collect 
information about the patient’s mother, father, and full siblings (routine pediatric oncology patient 
96%, or suspected CPS 98%). Participants were more likely to always ask about distantly related 
individuals if the patient was suspected to have a CPS, however, aunts/uncles and half siblings 
were asked about less often than grandparents despite the same degree of relationship to the patient. 
Grandparents were always included by 82.9% (150/181) of participants taking a family history for 
a routine patient whereas aunts/uncles were included by 57% (101/178). 
Since some evidence has found childhood cancer survivors may be eligible for genetic 
assessment and/or may have an underlying CPS, we asked how often respondents reviewed the 
family history. For most routine patients, family history was reviewed only if the patient mentioned 
an update (58.1%, 108/186) but if the patient was suspected to have a CPS, family history was 
reviewed most of the time (40.9%, 74/181). Some respondents specified time points (every 3-6 
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months, annually) for family history review, or indicated family history elicitation was outside of 
their scope of practice (ex. pathologists). 
Table 4. Family history assessment. 
  Routine  CPS 
  Number (%)  Number (%) 
Family members always included           
     Mother 175 96.2  178 98.3 
     Father 175 96.2   178 98.3 
     Siblings 174 95.6  178 98.3 
     Grandparents 150 82.9   168 93.9 
     Aunts/uncles 101 56.7  145 80.1 
     Half siblings 72 41.1   89 51.1 
     First cousins 57 32.2  122 68.2 
     Great aunts/uncles 22 12.8   70 39.8 
     Adopted siblings 13 7.8  16 9.8 
     Great grandparents 25 14.6   65 37.6 
     Step parents 7 4.2  12 7.3 
Family history review frequency           
     Never 1 0.5  0 0 
     Only if the patient mentions an update 108 58.1   67 37.0 
     Most of the time 40 21.5  74 40.9 
     Every appointment 18 9.7   27 14.9 
     Other 19 10.2  13 7.2 
3.3.5 Barriers to Complete Family History 
Given that family history information may be incomplete, we asked participants how often 
a list of barriers interfered with obtaining a family history. Overall, respondents felt the 
patient/parent’s lack of knowledge of the family history interfered a lot (43.2%, 79/183) or a great 
deal (16.4%, 30/183) with obtaining a family history. Eighty percent (46/183) felt this was the 
most challenging aspect. Most respondents disagreed with previously published data and indicated 
barriers to family history elicitation either interfered a little or not at all. These barriers included 
patient or parent’s anxiety (70.5%, 129/183), timing of family history elicitation in relation to 
diagnosis (53.6%, 98/183), and allocation of the provider’s time (55.2%, 101/183) (Figure 2A).  
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3.3.6 Barriers to Genetics Referrals 
Respondents indicated that hematologists/oncologists are the most appropriate practitioner 
to refer a child for assessment for a CPS, yet most participants rarely refer for this purpose. To 
investigate potential barriers to genetics referrals, participants were asked the extent to which each 
issue was a barrier to referral. Most participants indicated patient knowledge of family history was 
probably (59.4%, 107/180) or definitely (12.8%, 23/180) a barrier (Figure 2B). Other items 
identified by at least half of respondents to be barriers included priority given other immediate 
care needs (63.1%, 113/180), and patient understanding of genetic risk (52.2%, 93/178).  
Lack of available genetics services, and insufficient institutional resources were definitely 
not barriers for 51.1% (92/180) and 55% (99/180) of respondents, respectively, contrary to data 
from other settings. In addition, 41.1% (74/180) and 30% (54/180) of participants indicated patient 
eligibility for genetics services was probably not or definitely not a barrier to referrals for their 
patients. Other issues including familiarity with genetic conditions, limited time at appointments, 
cost and/or insurance coverage, and lack of referral guidelines were less likely to be considered 
barriers.  
Priority of the referral compared to other patient needs was determined to be the most 
challenging barrier for 24% (44/183) of respondents. Patient knowledge of family history was not 
only considered a barrier to collection of family history information but also to genetics referral 
(21.3%, 39/183), as was cost/insurance coverage (12%, 22/183). Other issues were acknowledged 
by less than 10% of the respondents as the most significant barrier to referral. 
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Figure 2. Barriers.  A. Barriers perceived by respondents to interfere with obtaining a complete family history. B. 
Barriers to genetics referral perceived by respondents. 
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3.4 Discussion 
3.4.1 Current Practices and Perceived Barriers to Referral 
This study assessed current referral practices of pediatric HCP for patients with a suspected 
CPS. To our knowledge, this is the first national study to investigate self-reported CPS guideline 
usage, and perceived barriers to pediatric genetics evaluation for CPS. The majority of respondents 
were attending pediatric hematologists/oncologists located throughout the United States 
representing a range of years in practice.  
Nearly 84% of respondents indicated that hematologists/oncologists were the most 
appropriate HCP to refer a patient with a suspected CPS for genetics evaluation. Of these 
participants, 72.7% were hematologists/oncologists themselves, yet close to three quarters of all 
participants indicated they only sometimes or rarely refer such patients. Recent data suggest the 
prevalence of CPS in the pediatric cancer population ranges from 7.6-35.5%.2-9 Thus respondents 
may have indicated they rarely refer patients because they rarely encounter appropriate patients 
for referral, or because other barriers prevent it. This study was designed to address the latter by 
investigating referral behaviors and the relationship to respondent demographics.  
The majority of respondents indicated they used guidelines to assess patients for referral 
and more than half were satisfied with the guidelines they use. Guideline use was associated with 
CPS clinical volume over 5%. Overall, participants were more likely to refer patients with 
malignancy and additional features of a CPS than they were for a specific type of cancer. PPGL 
was the only type of cancer the largest proportion of participants indicated they were likely to 
always refer for evaluation of a CPS, although guidelines recommend all index cases of PPGL be 
assessed for a CPS. These guidelines, published by American and European professional societies, 
41 
also recommend referral for cases of CPC, medulloblastoma, and sarcoma regardless of family 
history yet most respondents indicated they rarely refer patients with such malignancies for 
genetics evaluation despite their strong association with CPS.11,15,17 Regardless of guideline usage, 
these data suggest further education and guidance is required for providers, especially in a rapidly 
changing field such as genetics. In fact, tumor and germline sequencing in pediatric oncology has 
already discovered new candidate cancer predisposition genes, which may become relevant to 
patient care.6,48    
When it came to features associated with a CPS, likelihood to refer varied by the specific 
feature, and was generally not associated with guideline use except for immune deficiencies. 
Overall, respondents were likely to refer patients with malignancy and abnormal growth or 
excessive toxicity to cancer therapy, however, unfamiliarity with guidelines led to significantly 
decreased tendency to refer. The features described in this section of the survey were based on 
criteria described by European groups and thus may not be familiar to our American cohort.11,14 
Nonetheless, inconsistency to refer for each CPS feature suggests participants may consider 
additional factors and/or be using different guidelines to assess whether to refer a patient for a 
suspected CPS.  
In addition to guidelines, family history is often utilized to assess for a CPS, however, 
many factors may contribute to an incomplete family history.24,28,53,59-61 In this study, the most 
challenging aspect of obtaining a family history identified by participants was the patient/parent’s 
lack of knowledge about the family. Respondents also indicated that patient/parent’s lack of family 
history knowledge was the most challenging barrier to genetics referral. Together these data 
suggest both physician and patient factors contribute to incomplete family history documentation 
and suggest respondents rely on complete, positive family histories to elicit referral.18 The 
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American Society of Clinical Oncology (ASCO) has released a statement to define the minimum 
family history information required for assessment and to provide guidance on interpretation.81  
Nonetheless, survey respondents reported they do not always collect a full three-generation 
pedigree, the gold standard in genetics, or a two-generation pedigree as recommended by ASCO, 
which is concordant with data from other studies.22,27,81 Patient knowledge may limit family history 
elicitation, but should not prevent referral of patients with high-risk tumors for evaluation.  
 Patient needs are prioritized during oncology visits and family history elicitation may 
initially be deferred, but research in the pediatric cancer survivor setting has illustrated the 
importance of frequent family history review.1,42,44 As expected, respondents indicated they 
reviewed family history more often for patients with a suspected CPS, yet only 14.9% reviewed 
family history at every appointment. Instead, the most common answers were most of the time or 
if the patient mentioned an update. Some respondents may see their patients more often than the 
family history would be expected to change thus decreasing the proportion of physicians who 
would review history at every appointment, however, patients are less likely to mention updates 
unprompted and thus these responses may represent missed referral opportunities.24  
In addition to family history review, cancer predisposition evaluation may be considered 
low priority given other patient needs.1,15 Nearly two thirds of respondents indicated priority was 
a barrier to genetics referral and it was considered the most significant barrier by 24%. Indeed, the 
majority of participants surveyed were hematologists/oncologists and pediatric surgeons whose 
main concerns are focused on the acute needs of their patients. Of note, limited time was not 
identified as a barrier by most respondents. Evidence suggests that HCP who deem genetics 
integral to their practice are more likely to refer.65 While referral to another specialist at an 
overwhelming and busy time for the family may not take top priority for the treating physician, 
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identification of a CPS can have immediate effects on the patient’s siblings, parents, and other 
family members and should be addressed in a timely manner.1 Patients with an underlying CPS 
have been identified by family history review in survivorship clinics which may be an option for 
family history review for some practitioners.42,44 Alternatively, family history could be elicited by 
a genetic counselor shortly after diagnosis, or collected briefly by the oncologist at diagnosis and 
reviewed by a genetic counselor following completion of therapy. This would ensure immediate 
care needs were met and that the patient was appropriately assessed before discharge.  
This survey focused on barriers to physician-initiated referrals. Interestingly, patient 
understanding of genetic risk, a patient-centered issue, was considered a barrier by over half of 
respondents. This issue is often considered in the context of referral uptake rather than the initiation 
of the referral itself.82 Other groups have addressed this problem successfully by embedding 
genetic counseling services into adult oncology clinics.72,73 Further information is required to 
understand why physicians considered this a barrier to referral, though there is evidence from 
primary care research that indicates physicians with less confidence in their own ability to explain 
genetics concepts to their patients are less likely to refer to a genetics professional.25  
Contrary to other studies, access to genetics services, professionals, and resources 
generally and within the respondent’s institution were not perceived as barriers to referral.19,25,30,64 
In fact, almost 60% of participants reported their institution has a cancer predisposition clinic and 
most participants receive helpful feedback on referrals. While most participants also indicated 
access to a genetic counselor, geneticist, or other colleague with expertise in CPS for formal or 
informal consultations, further implementation of genetics into the pediatric oncology clinic may 
be beneficial to the identification of patients with an underlying CPS, especially since over a 
quarter of respondents do not receive feedback following referral.83 While nearly half of 
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respondents indicated they participate in molecular/genetics tumor boards, 31.9% of respondents 
indicated their institution conducts tumor boards but they do not attend. This may represent an 
opportunity for genetic counselors and others with expertise in CPS to educate colleagues and 
increase referrals, and participation from multiple departments should be encouraged. This may 
also ensure consistent referral practices within an institution, as our data suggests only 16% of 
respondents follow institutional referral guidelines.  
Over half of respondents surveyed indicated cost/insurance coverage and patient eligibility 
for genetic services were not barriers to genetics referrals, however cost/insurance coverage was 
identified as the most challenging barrier to referral by 12% of respondents. This suggests it is a 
significant issue to a small number of providers. The severity of these issues may depend on 
regional insurance coverage. Data collected for this study are not large enough to make conclusions 
on this matter, however, these are commonly reported barriers to genetics referral in other practice 
settings as well.30-32,64,67 Nonetheless, it is encouraging that cost/insurance coverage and patient 
eligibility are not major barriers to referral for CPS evaluation for these participants. 
Although most participants surveyed use referral guidelines, almost half of those who do 
not indicated a lack of guideline availability or unawareness of guidelines as the reason. One 
respondent commented that guidelines would be more useful if risk for a CPS was defined relative 
to family history, whereas others indicated their institutions refer all pediatric oncology patients. 
These comments demonstrate a lack of consensus on which patients should be referred for CPS 
evaluation and how strictly guidelines are followed by the pediatric oncology community. This is 
a problem others have documented.52,84 While it may not be feasible for each cancer predisposition 
clinic to accept referrals of all pediatric oncology patients, guidelines aim to ensure a balance 
between the benefit of diagnosing children with an underlying CPS and the risks of over-referring 
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patients to genetics/cancer predisposition clinics. This must also be balanced with the availability 
of genetics professionals to prevent overwhelming the genetics workforce, of which there is a 
documented shortage.85,86 Therefore, efforts should be made to develop and distribute sensitive, 
specific, easy-to-use guidelines for CPS evaluation and to encourage consultation between 
specialties to increase appropriate referrals.  
Evidence suggests lack of adherence to guidelines is closely related to genetics knowledge 
and perceived clinical utility.57,69 The majority of respondents reported they received adequate 
genetics education during their training (Appendix A, Table 2) and stated scientific literature, 
personal communications with genetics professionals, and multidisciplinary tumor board meetings 
as the major channels through which they continue to obtain information. Over half of respondents 
also indicated familiarity with genetic conditions was not a barrier to genetics referral. This study 
was not designed to measure genetics knowledge, but it does suggest that further education may 
be helpful to aid survey respondents in identification of patients who may benefit from genetics 
evaluation for a CPS. 
Gaps in genetics knowledge, family history elicitation, logistical details, and referral 
recommendations may prevent or delay referrals for CPS evaluation. Genetics professionals 
including geneticists, genetic counselors, and/or other HCP with expertise in CPS are specially 
trained to address these issues. While our data suggest many pediatric oncology providers surveyed 
consult their genetics colleagues, there is room to improve. Genetic counselors may offer a 
valuable set of skills to address both physician and patient-centered barriers, and utilization of their 
skills has proven beneficial in similar settings.72,73 However, a recent survey of pediatric HCP in a 
multi-disciplinary hematology/oncology clinic found that providers perceive many genetic 
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counselor roles as shared and suggests the role of genetic counselors within a multi-disciplinary 
team may require clarification of expectations to prioritize their time and effort.87   
3.4.2 Limitations 
Limitations to this study include the low response rate which may have been due to the 
short data collection phase, and availability of respondents. Participants were not asked to specify 
which guidelines they use, preventing further association of responses with specific guideline 
recommendations. Referral behavior questions addressed likelihood or frequency of referral and 
wording was not consistent between these questions which may have changed respondents’ 
interpretations. For instance, participants were asked how often they refer patients with specific 
cancer types. This may have been interpreted as how often they encounter and refer such patients 
rather than how often they refer a patient given that specific malignancy. This survey focused on 
behaviors and attitudes and did not quantify referral rates. Although the survey was piloted, it was 
not formally validated with content validity or reliability measures.88  
3.4.3 Future Directions 
The majority of survey respondents reported the use of referral guidelines to aid in their 
decision making, yet guideline use was not significantly correlated with referral frequency for a 
number of factors in this study. Additional research is required to elucidate which specific 
guidelines pediatric oncology HCP use, and how closely they are followed. Efforts may be focused 
on enhanced distribution of guidelines as some participants were unaware of guidelines for referral 
of patients with a suspected CPS.  
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Future studies may quantify pediatric oncology healthcare provider’s knowledge about 
CPS to elucidate the relationship between CPS knowledge and guideline adherence, or genetics 
referral. Lastly, survey respondents represent a small proportion of all pediatric oncology HCP; 
future work will aim to collect data from a more representative sample of hematology/oncology 
practitioners and other pediatric providers to understand the perspectives of the care team as a 
whole.  
3.5 Conclusion 
The use of NGS in pediatric cancer has demonstrated cancer predisposition syndromes 
have a broader phenotypic spectrum than previously understood. Identification of individuals with 
an underlying CPS is important for proper management and surveillance of the individual as well 
as for their family. This is especially important from a public health perspective, as cancer 
surveillance and disease management differ for patients with a CPS, and early detection of 
secondary malignancies may be missed by standard treatment-based surveillance protocols. 
This study indicates hematologists/oncologists believe they are the most appropriate 
providers to refer patients in whom a CPS is suspected, yet most rarely refer patients for CPS 
evaluation. Respondents demonstrated lack of consensus on which patients should be referred for 
genetic evaluation of a CPS suggesting further education, and clearer guidelines are required to 
identify this population of patients. We encourage the implementation of genetic counselors or 
other genetics specialists within pediatric oncology clinics to help address these barriers. Genetic 
counselors are a valuable resource, specially trained to elicit family histories, assess patient/family 
risk, and address the unique psychosocial aspects of genetics in the context of pediatric cancer 
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care. Furthermore, genetic counselors are knowledgeable about emerging genetic research and 
advances in the field, making them well suited to disseminate this information and educate their 
pediatric oncology colleagues.  
The results of this study are comparable to findings in adult oncology, but this is the first 
study the authors are aware of in pediatric oncology that investigates these issues. Overall, these 
data demonstrate physician, patient, and system level barriers to genetics evaluation for children 
with a suspected CPS. Both patient and physician factors prevent the collection of in-depth family 
history information but this should not preclude referral. Education about features and high-risk 
cancers associated with CPS, more widely distributed referral recommendations, and further 
implementation of genetics experts into pediatric oncology practices may contribute to increased 
genetics referrals and ultimately improve recognition of at-risk patients.  
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4.0 Genetic Counseling and Public Health Significance 
This survey aimed to evaluate barriers to genetics referrals for patients with a suspected 
CPS, which fits with one of the ten essential public health services described by the Centers for 
Disease Control and Prevention to “evaluate effectiveness, accessibility, and quality of personal 
and population-based health services”.89 By evaluating how patients are currently referred, we 
have identified barriers and have offered recommendations on how appropriate referrals could be 
increased.  
The identification of patients who may have an underlying CPS addresses other essential 
public health services such as i) monitoring health status, ii) diagnosing health problems in the 
community, iii) informing, educating and, empowering people about health issues, and iv) linking 
people to needed personal health services.89 Such referrals aid in monitoring health status by 
identifying and diagnosing patients at increased risk to develop cancer. This extends to the larger 
community since CPS are often hereditary and the diagnosis of one child has implications for the 
rest of their family. Furthermore, diagnosis of patients with a CPS may result in management 
changes and preventative measures which have been shown to be cost effective, and to improve 
patient outcomes.13,36,90 
The act of referring at-risk patients to a genetics professional has the potential to inform, 
educate, and empower patients and their families with information about a CPS. These referrals 
often involve genetic counselors who are trained to educate, empathize, and facilitate informed 
decision making for their patients.91  Thus, genetic counselors not only help address some of the 
gaps in knowledge that the referring provider may have, but they possess additional valuable skills 
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to aid in patient education and empowerment. Referrals themselves also link patients to HCP 
fulfilling another essential public health service.  
In summary, this study identified barriers to genetics referrals for a specific population of 
patients who may have an underlying CPS. These issues are not only barriers to individual patients, 
but to their families as well. Multidisciplinary teams and cooperation between specialties has the 
opportunity to benefit patient care. Genetic counselors have expertise in family history assessment, 
knowledge about CPS, and skills required to address the psychosocial aspects of caring for this 
population which makes them an integral part of this team. Furthermore, by sharing responsibilities 
such as family history elicitation and assessment, or educating colleagues about CPS, genetic 
counselors allow other HCP to focus on different issues.   
This study found that pediatric oncology healthcare providers use different criteria to 
determine whether to refer patients for evaluation of a CPS. Factors influencing the decision to 
refer include provider knowledge about CPS, priority given the patient’s immediate care needs, 
family history, and patient understanding of genetic risk. Following the identification of these 
barriers, we recommend the adoption of referral guidelines and further implementation and 
utilization of genetic counselors trained to address many of the barriers mentioned above. 
Interventions such as those described above may increase appropriate referrals for patients with a 
CPS, ultimately improving patient and family outcomes.  
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 Supplemental Figures 
Appendix Table 1. Family history importance. 
  Routine   CPS 
  Number (%)   Number (%) 
Family history is essential to assessment for all new pediatric 
oncology patients/patients with a suspected CPS           
     Strongly agree 171 91.4  176 94.6 
     Somewhat agree 15 8.0   9 4.8 
     Neither agree nor disagree 0 0.0  0 0.0 
     Somewhat disagree 0 0.0   1 0.5 
     Strongly disagree 1 0.5  0 0.0 
 













  Number (%) 
Do you feel you received adequate education in 
genetics during your professional training?     
     Definitely yes 33 17.7 
     Probably yes 79 42.5 
     Uncertain 18 9.7 
     Probably not 46 24.7 
     Definitely not 10 5.4 
52 
Appendix Table 3. Genetic testing. 
  Count % 
Have you ordered genetic testing for patients with a 
suspected CPS?     
     Never 23 12.4 
     Rarely (a few times per year) 89 47.8 
     Sometimes (once per month) 44 23.7 
     Often (several times per month) 26 14.0 
     Frequently (several times per week) 4 2.2 
How comfortable are you interpreting somatic genetic 
test results for patients with a suspected CPS?     
     Extremely uncomfortable 17 9.2 
     Somewhat uncomfortable 46 25.0 
     Neither comfortable nor uncomfortable 34 18.5 
     Somewhat comfortable 59 32.1 
     Extremely comfortable 28 15.2 
How comfortable are you interpreting germline 
genetic test results for patients with a suspected CPS?     
     Extremely uncomfortable 16 8.6 
     Somewhat uncomfortable 52 28.0 
     Neither comfortable nor uncomfortable 31 16.7 
     Somewhat comfortable 66 35.5 
     Extremely comfortable 22 11.8 
Who routinely interprets genetic testing results in 
your clinic? Select all that apply     
     I do 85 45.9 
     Medical geneticist 94 50.8 
     Advanced practice provider 5 2.7 
     Pathologist 37 20.0 
     Genetic counselor 95 51.4 
     Team approach 77 41.6 

















Most of the 
time Always Total 
  Count % Count % Count % Count % Count %   
Mother 0 0 0 0 0 0 7 3.8 175 96.2 182 
Father 0 0 0 0 1 0.5 6 3.3 175 96.2 182 
Siblings 0 0 0 0 1 0.5 7 3.8 174 95.6 182 
Grandparents 0 0 5 2.8 4 2.2 22 12.2 150 82.9 181 
Aunts/uncles 2 1.1 17 9.6 14 7.9 44 24.7 101 56.7 178 
First cousins 9 5.1 45 25.4 17 9.6 49 27.7 57 32.2 177 
Great aunts/uncles 31 18.0 70 40.7 19 11.0 30 17.4 22 12.8 172 
Adopted siblings 103 62.0 33 19.9 6 3.6 11 6.6 13 7.8 166 
Half siblings 22 12.6 38 21.7 14 8.0 29 16.6 72 41.1 175 
Great grandparents 34 19.9 69 40.4 17 9.9 26 15.2 25 14.6 171 
Step parents 102 61.8 36 21.8 6 3.6 14 8.5 7 4.2 165 
 
 





Most of the 
time Always Total 
  Count % Count % Count % Count % Count %   
Mother 0 0 0 0 0 0 3 1.7 178 98.3 181 
Father 0 0 0 0 0 0 3 1.7 178 98.3 181 
Siblings 0 0 0 0 0 0 3 1.7 178 98.3 181 
Grandparents 0 0 0 0 0 0 11 6.1 168 93.9 179 
Aunts/uncles 1 0.6 2 1.1 7 3.9 26 14.4 145 80.1 181 
First cousins 2 1.1 13 7.3 13 7.3 29 16.2 122 68.2 179 
Great aunts/uncles 10 5.7 44 25.0 19 10.8 33 18.8 70 39.8 176 
Adopted siblings 99 60.4 32 19.5 7 4.3 10 6.1 16 9.8 164 
Half siblings 18 10.3 27 15.5 16 9.2 24 13.8 89 51.1 174 
Great grandparents 14 8.1 45 26.0 15 8.7 34 19.7 65 37.6 173 
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 Recruitment Email 
Dear Healthcare Provider,  
My name is Rosemarie Venier. I am currently pursuing a graduate degree in genetic 
counseling at the University of Pittsburgh. This email serves as an invitation to participate in an 
online survey to assess the barriers to genetics referrals for pediatric oncology patients with a 
suspected cancer predisposition syndrome (CPS).  
Identification of individuals with a CPS is critical to inform appropriate management and 
surveillance, yet it is predicted that these individuals are underdiagnosed. Furthermore, there are 
limited published data on barriers to genetics services in pediatric care. We are interested in the 
pediatric healthcare provider’s role in referral of patients with a suspected CPS to genetics services. 
We aim to elucidate these details by assessing genetics knowledge, accessibility to genetics 
services and genetic testing practices of pediatric healthcare providers.  
Eligible participants are healthcare providers involved in the care of pediatric oncology 
patients. Pediatric is defined as birth to age 26 years. You must be currently located in the United 
States of America to complete the survey. The survey will take approximately 10 minutes to 
complete. Periodic reminder emails will be sent to encourage survey completion. No direct benefits 
apply to participants, however, information obtained may inform future practice. No personal 
contact data will be associated with survey responses. Risks include the possibility of a 
confidentiality breach of names and email addresses. This risk is reduced by storing information 
on a secure University of Pittsburgh Medical Center server.   
By completing the survey at the link below, you agree to participate in this research study. 
Participation is voluntary. You may stop the survey at any point and return to complete it using 
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the appropriate link below. Incomplete survey responses will be recorded after 2 weeks of 
inactivity. All response data will be anonymous. Survey data without identifiers may be shared 
with individuals outside the study team. This survey has been approved by the Institutional Review 
Board at the University of Pittsburgh. Additional questions can be addressed to the principal 
investigator, Rosemarie Venier at rev24@pitt.edu. The deadline to complete this survey is 
[deadline]. 
Please use this personal link to access the survey. [personal link] 
I encourage you to share this email with eligible colleagues, who should use the following link to 
access the survey. [anonymous link] 
Sincerely, 
Rosemarie Venier, MSc 
MS Genetic Counseling Candidate 




Start of Block: Demographics 
 








What is your level of training? Select all that apply. 
▢MD (staff physician)  
▢MD (fellow/resident)  
▢PhD  
▢Advanced practice provider (PA, NP)  
▢Nurse  
▢Genetic counselor  














Do you feel you received adequate education in genetics during your professional training? 
oDefinitely yes  
oProbably yes  
oUncertain  
oProbably not  





What sources do you obtain information about genetics from? Select all that apply. 
▢Scientific literature  
▢Fellowship/training  
▢CME activities  
▢Personal communication with genetics professionals  
▢Multi-disciplinary tumor board meeting  





What is your age? 









How many years have you been practicing? 
oCurrently training  








In which state do you see most patients? 




What setting do you practice in? Select all that apply. 
▢Children's hospital within an academic/university center (not freestanding)  
▢Freestanding children's hospital  
▢Private practice  





What is your clinical volume of new pediatric oncology patients per year? 
oLess than 100  
o100-250  
oMore than 250  




What percentage of your patients have a diagnosed cancer predisposition syndrome (CPS)? 
(Ex. Li-Fraumeni syndrome, Beckwith-Wiedemann syndrome, Cowden syndrome) 
oNone  
oLess than 5%  
o5-10%  












Display This Question: 
If Do you have access to a genetics specialist (geneticist, genetic counselor)? = Yes 
 
What type of genetics specialist do you have access to? Select all that apply. 
▢Geneticist  
▢Certified genetic counselor  





End of Block: Demographics 
 
Start of Block: Family History 
 
Family history is essential to the assessment of all new pediatric oncology patients. 
oStrongly agree  
oSomewhat agree  
oNeither agree nor disagree  
oSomewhat disagree  





Family history is essential to the assessment of suspected cancer predisposition 
syndrome patients. 
oStrongly agree  
oSomewhat agree  
oNeither agree nor disagree  
oSomewhat disagree  




Following an initial appointment for a new pediatric oncology referral, how often do you 
review family history (ex. asking if there have been new diagnoses in the family)? 
oNever  
oOnly if the patient mentions an update  
oMost of the time  






Following an initial appointment for a new pediatric oncology referral with a suspected 
cancer predisposition syndrome, how often do you review family history (ex. asking if there 
have been new diagnoses in the family)? 
oNever  
oOnly if the patient/parent mentions an update  
oMost of the time  






A new pediatric oncology referral presents to your clinic. When eliciting family cancer 
history, which specific family members do you inquire about because it is relevant to your 
assessment? 
 Never Sometimes 
About 
half the time 
Most 
of the time 
Always 
Mother  o o o o o 
Father  o o o o o 
Siblings  o o o o o 
Grandparents  o o o o o 
Aunts/uncles  o o o o o 
First cousins  o o o o o 
Great 
aunts/uncles  o o o o o 
Adopted siblings  o o o o o 
Half siblings  o o o o o 
Great 
grandparents  o o o o o 






A new pediatric oncology referral with a suspected cancer predisposition syndrome 
presents to your clinic. When eliciting family cancer history, which specific family members do 
you inquire about because it is relevant to your assessment? 
 Never Sometimes 
About 
half the time 
Most 
of the time 
Always 
Mother  o o o o o 
Father  o o o o o 
Siblings  o o o o o 
Grandparents  o o o o o 
Aunts/uncles  o o o o o 
First cousins  o o o o o 
Great 
aunts/uncles  o o o o o 
Adopted siblings  o o o o o 
Half siblings  o o o o o 
Great 
grandparents  o o o o o 






How often do the following interfere with obtaining a family history? 
 None at all A little 
A moderate 
amount 
A lot A great deal 
Patient/parent's lack 
of knowledge of family  o o o o o 
Patient/parent's 
anxiety  o o o o o 
Timing of conversation 
relative to diagnosis  o o o o o 
Allocation of provider's 
time  o o o o o 





What is the most challenging aspect of obtaining a family history? 
oPatient/parent's lack of knowledge of family  
oPatient/parent's anxiety  
oTiming of conversation relative to diagnosis  
oAllocation of provider's time  





End of Block: Family History 
 




To what extent are the following items barriers to genetics referrals in your practice? 
 Definitely not Probably not Probably yes Definitely yes 
Limited time at 
appointments  o o o o 
Familiarity with 
genetic conditions  o o o o 
Lack of available 
genetics services  o o o o 
Patient knowledge 
of family history  o o o o 
Patient 
understanding of 
genetic risk  o o o o 
Cost/insurance 
coverage  o o o o 
Patient eligibility for 
genetic services  o o o o 
Insufficient 
resources within 
institution (lack of 
genetics 
professionals)  
o o o o 
Lack of referral 




needs, etc.)  
o o o o 
Other (please 






What is the most significant barrier to genetics referral in your practice? 
oLimited time at appointments  
oFamiliarity with genetic conditions  
oLack of available genetics services  
oPatient knowledge of family history  
oPatient understanding of genetic risk  
oCost/insurance coverage  
oPatient eligibility for genetic services  
oInsufficient resources within institution (lack of genetics professionals)  
oLack of referral guidelines  
oPriority (given patient's treatment, immediate care needs, etc.  





End of Block: Barriers 
 
Start of Block: Genetics Accessibility 
 
How often do you refer patients to genetics for a cancer predisposition evaluation? 
oNever  
oRarely (a few times per year)  
oSometimes (once per month)  
oOften (several times per month)  












Display This Question: 
If Does your institution have a cancer predisposition clinic? = Yes 
 
What department is the cancer predisposition clinic part of? 
oHematology/oncology  
oMedical genetics  





Do you use formal/published guidelines when deciding whether to refer to genetics? For example, 














Display This Question: 
If Do you use formal/published guidelines when deciding whether to refer to genetics? For example, N... != No 
 
How satisfied are you with the referral guidelines you use? 
oExtremely satisfied  
oSomewhat satisfied  
oNeither satisfied nor dissatisfied  
oSomewhat dissatisfied  





What is the main reason for not using formal referral guidelines? 
oLack of available guidelines  
oConflicting guidelines from different sources  
oFeel confident in referring without them  
oI do use them  




Do you receive feedback from a genetics clinic regarding your referrals? 






Display This Question: 
If Do you receive feedback from a genetics clinic regarding your referrals? (Inappropriate/appropria... = Yes 
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Do you consult a genetics specialist or cancer predisposition oncologist when you suspect 
a patient has a cancer predisposition syndrome? For the purpose of this question, genetics specialist 







Display This Question: 
If Do you consult a genetics specialist or cancer predisposition oncologist when you suspect a patie... = No 
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Would consulting a genetics specialist or cancer predisposition oncologist be helpful when 







Do you participate in institutional molecular/genetics tumor boards? 
oYes  
oNo, but there are tumor boards in my institution  




End of Block: Genetics Accessibility 
 




Have you ordered genetic testing for patients with a suspected cancer predisposition 
syndrome? 
oNever  
oRarely (a few times per year)  
oSometimes (once per month)  
oOften (several times per month)  




How comfortable are you interpreting somatic genetic test results for patients with a 
suspected cancer predisposition syndrome? 
oExtremely uncomfortable  
oSomewhat uncomfortable  
oNeither comfortable nor uncomfortable  
oSomewhat comfortable  





How comfortable are you interpreting germline genetic test results for patients with a 
suspected cancer predisposition syndrome? 
oExtremely uncomfortable  
oSomewhat uncomfortable  
oNeither comfortable nor uncomfortable  
oSomewhat comfortable  





Who routinely interprets genetic testing results in your clinic? Select all that apply. 
▢I do  
▢Medical geneticist  
▢Advanced practice provider  
▢Pathologist  
▢Genetic counselor  
▢Team approach  





How are positive genetic test results (pathogenic mutation detected) routinely delivered to 
the patients in your clinic? Select all that apply. 
▢In person  
▢On the phone  
▢Voicemail  
▢Letter  




End of Block: Genetic Testing 
 
Start of Block: Knowledge 
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A patient presents to your clinic with malignancy. How likely are you to consider a cancer 













from tumor that 
indicate somatic 
mutation in a 
predisposition 
gene (ex. TP53, 
PTEN)  
o o o o o 
Genetic results 
from tumor that 
suggest a 
germline 
mutation in a 
predisposition 
gene (ex. TP53, 
PTEN)  
o o o o o 
Congenital 
anomalies  o o o o o 
Dysmorphic 
features  o o o o o 
Developmental 
delay/intellectual 







o o o o o 
Environmental 





to sun, vascular 
lesions)  
o o o o o 
Hematological 
abnormalities 
(not explained by 
current 
malignancy)  
o o o o o 
86 
Immune 






o o o o o 
Excessive toxicity 
to cancer 













How often do you refer patients with the following diagnosis for a cancer predisposition 
evaluation? 




Osteosarcoma  o o o o o 
Acute myeloid leukemia  o o o o o 
Embryonal rhabdomyosarcoma  o o o o o 
Alveolar rhabdomyosarcoma  o o o o o 
Neuroblastoma  o o o o o 
Choroid plexus carcinoma  o o o o o 
Wilms tumor  o o o o o 
Medulloblastoma  o o o o o 
High grade glioma  o o o o o 
Low grade glioma  o o o o o 
Pheochromocytoma/paraganglioma  o o o o o 
Ewing sarcoma  o o o o o 






Who is the most appropriate healthcare practitioner to refer a patient with a cancer 
predisposition syndrome to genetics? 
oHematologist/Oncologist  
oMedical geneticist  
oAdvanced practice provider  
oPathologist  
oGenetic counselor  
oPrimary care physician  
oSurvivorship clinician  





Who is the most appropriate healthcare practitioner to diagnose a patient with a cancer 
predisposition syndrome? 
oHematologist/Oncologist  
oMedical geneticist  
oAdvanced practice provider  
oPathologist  
oGenetic counselor  
oPrimary care physician  
oSurvivorship clinician  




End of Block: Knowledge 
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